Immunotherapeutics companion diagnostic - ImmunID

Drug Profile

Immunotherapeutics companion diagnostic - ImmunID

Alternative Names: ImmunIG®; ImmunTraCkeR®; Ipilimumab companion diagnostic - ImmunID; SCIB 1 companion diagnostic - ImmunID

Latest Information Update: 26 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunID
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Malignant melanoma

Most Recent Events

  • 23 Feb 2016 ImmunID and the Memorial Sloan Kettering Cancer Center agree to co-develop ipilimumab companion diagnostic for Solid tumours
  • 15 Feb 2016 ImmunTraCkeR® receives CE mark approval in Europe
  • 30 Jul 2015 ImmunID and Scancell agree to co-develop SCIB 1 companion diagnostic for Malignant melanoma
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top